We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCEL icon
76
Avita Medical
RCEL
$251M
$6.17M 0.32%
934,233
+75,282
+9% +$451K
TERN
77
DELISTED
Terns Pharmaceuticals
TERN
$6.16M 0.32%
605,079
-123,521
-17% -$822K
TELA icon
78
TELA Bio
TELA
$32.3M
$5.98M 0.31%
520,079
– –
TGTX icon
79
TG Therapeutics
TGTX
$7.58B
$5.97M 0.31%
504,829
-695,984
-58% -$5.05M
LNTH icon
80
Lantheus
LNTH
$6.57B
$5.95M 0.31%
116,665
-7,100
-6% -$438K
IMDX
81
Insight Molecular Diagnostics
IMDX
$147M
$5.79M 0.3%
902,814
– –
ADPT icon
82
CALL
Adaptive Biotechnologies
ADPT
$4.02B
$5.73M 0.3%
+750,000
New +$5.84M
TECH icon
83
Bio-Techne
TECH
$11.3B
$5.64M 0.29%
+68,000
New +$5.4M
TMDX icon
84
Transmedics
TMDX
$3.02B
$5.55M 0.29%
90,000
-30,000
-25% -$1.59M
TMDX icon
85
PUT
Transmedics
TMDX
$3.02B
$5.55M 0.29%
+90,000
New +$4.78M
MRTX
86
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.54M 0.29%
+122,200
New +$7.91M
SYNH
87
CALL
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$5.5M 0.28%
+150,000
New +$5.93M
PFE icon
88
CALL
Pfizer
PFE
$150B
$5.12M 0.26%
100,000
– –
COO icon
89
Cooper Companies
COO
$15B
$5.09M 0.26%
61,600
-9,392
-13% -$693K
KALV
90
DELISTED
KalVista Pharmaceuticals
KALV
$4.95M 0.26%
732,702
-100,000
-12% -$536K
RCM
91
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.93M 0.25%
450,000
+189,600
+73% +$2.41M
ISEE
92
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.92M 0.25%
229,600
-400,000
-64% -$8.54M
CNMD icon
93
PUT
CONMED
CNMD
$1.48B
$4.91M 0.25%
+55,400
New +$4.6M
SDGR icon
94
Schrodinger
SDGR
$1.39B
$4.86M 0.25%
260,000
– –
PHG icon
95
PUT
Philips
PHG
$26.2B
$4.5M 0.23%
350,361
-116,788
-25% -$1.41M
A icon
96
PUT
Agilent Technologies
A
$41.9B
$4.49M 0.23%
+30,000
New +$4.28M
GERN icon
97
CALL
Geron
GERN
$1.01B
$4.39M 0.23%
1,814,600
+112,000
+7% +$251K
CTKB icon
98
Cytek Biosciences
CTKB
$621M
$4.3M 0.22%
420,749
-106,415
-20% -$1.43M
BNTX icon
99
BioNTech
BNTX
$23.3B
$4.24M 0.22%
+28,195
New +$4.34M
CGC
100
CALL
Canopy Growth
CGC
$431M
$4.04M 0.21%
+175,000
New +$5.4M
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.